Download

Full Text

See more details

X (1)

Mendeley (24)

4

CITATIONS

4 Total citations

0 Recent citations

0.99 Field Citation Ratio

0.1 Relative Citation Ratio

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Stone, M.A., Charpentier, G., Doggen, K., Kuss, O., Lindblad, U., Kellner, C., et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 36 (2013), 2628–2638.
• Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
• DeFronzo, R.A., Ferrannini, E., Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991), 173–194.
• Oliveras, A., de la Sierra, A., Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens 28 (2014), 213–217.
• White, W.B., Turner, J.R., Sica, D.A., Bisognano, J.D., Calhoun, D.A., Townsend, R.R., et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda. J Am Soc Hypertens 8 (2014), 743–757.
• Muxfeldt, E.S., de Souza, F., Salles, G.F., Resistant hypertension: a practical clinical approach. J Hum Hypertens 27 (2013), 657–662.
• Bangalore, S., Davis, B.R., Cushman, W.C., Pressel, S.L., Muntner, P.M., Calhoun, D.A., et al. Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT. Am J Med 130 (2017), 439–489.
• Ferrannini, E., Cushman, W.C., Diabetes and hypertension: the bad companions. Lancet 380 (2012), 601–610.
• Scheen, A.J., Pharmacotherapy of “treatment resistant” type 2 diabetes. Expert Opin Pharmacother 18 (2017), 503–515.
• American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 40 (2017), S1–S135.
• Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
• Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 22 (2016), 84–113.
• Bejan-Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B., Audier, P., Brabant, Y., et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 41 (2015), 195–201.
• Crowley, M.J., Holleman, R., Klamerus, M.L., Bosworth, H.B., Edelman, D., Heisler, M., Factors associated with persistent poorly controlled diabetes mellitus: clues to improving management in patients with resistant poor control. Chronic Illn 10 (2014), 291–302.
• Yin, J., Yeung, R., Luk, A., Tutino, G., Zhang, Y., Kong, A., et al. Gender, diabetes education, and psychosocial factors are associated with persistent poor glycemic control in patients with type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 8 (2016), 109–119.
• Aronson, R., Orzech, N., Ye, C., Goldenberg, R., Brown, V., Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database. J Diabetes 8 (2016), 76–85.
• Khan, H., Lasker, S.S., Chowdhury, T.A., Exploring reasons for very poor glycaemic control in patients with Type 2 diabetes. Prim Care Diabetes 5 (2011), 251–255.
• Abdelmoneim, A.S., Eurich, D.T., Light, P.E., Senior, P.A., Seubert, J.M., Makowsky, M.J., et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
• International Diabetes Federation (IDF), Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012 https://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf [Accessed April 5, 2017].
• National Institute for Health and Care Excellence (NICE), Type 2 diabetes in adults: management. 2016 http://www.nice.org.uk/guidance/ng28 [Accessed April 5, 2017].
• Haute Autorité de Santé (HAS), Stratégie médicamenteuse du contrôle glycémique du diabète de type 2: recommandations. 2013 https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf [Accessed April 5, 2017].
• Palmer, S.C., Mavridis, D., Nicolucci, A., Johnson, D.W., Tonelli, M., Craig, J.C., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
• McIntosh, B., Cameron, C., Singh, S.R., Yu, C., Dolovich, L., Houlden, R., Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med 6 (2012), e62–e74.
• Zhong, X., Zhang, T., Liu, Y., Wei, X., Zhang, X., Qin, Y., et al. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis. Diabetes Res Clin Pract 109 (2015), 451–460.
• Polonsky, W.H., Fisher, L., Guzman, S., Villa-Caballero, L., Edelman, S.V., Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 28 (2005), 2543–2545.
• Ross, S.A., Tildesley, H.D., Ashkenas, J., Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 27:3 (2011), 13–20.
• Petrak, F., Stridde, E., Leverkus, F., Crispin, A.A., Forst, T., Pfutzner, A., Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care 30 (2007), 2199–2204.
• Wang, H.F., Yeh, M.C., Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review. J Adv Nurs 68 (2012), 743–757.
• Cramer, J.A., A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004), 1218–1224.
• Bailey, C.J., Kodack, M., Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 65 (2011), 314–322.
• Grimaldi, A., Penfornis, A., Consoli, S., Falissard, B., Eymard, E., Williams, P., et al. Breaking barriers to effective type 2 diabetes management: findings from the use of the OPTIMA(c) questionnaire in clinical practice. Adv Ther 33 (2016), 1033–1048.
• Reach, G., Pechtner, V., Gentilella, R., Corcos, A., Ceriello, A., Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab, 43, 2017.
• Grant, R., Adams, A.S., Trinacty, C.M., Zhang, F., Kleinman, K., Soumerai, S.B., et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 30 (2007), 807–812.
• Reach, G., Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab 34 (2008), 382–385.
• Khunti, K., Wolden, M.L., Thorsted, B.L., Andersen, M., Davies, M.J., Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36 (2013), 3411–3417.
• Halimi, S., Balkau, B., Attali, C., Detournay, B., Amelineau, E., Blickle, J.F., Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. Diabetes Metab 38:Suppl 3 (2012), S36–S46.
• Kunt, T., Snoek, F.J., Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 164 (2009), 6–10.
• de Pablos-Velasco, P., Parhofer, K.G., Bradley, C., Eschwege, E., Gonder-Frederick, L., Maheux, P., et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 80 (2014), 47–56.
• Simon, D., de Pablos-Velasco, P., Parhofer, K.G., Gonder-Frederick, L., Duprat Lomon, I., Vandenberghe, H., et al. Hypoglycaemic episodes in patients with type 2 diabetes—risk factors and associations with patient-reported outcomes: The PANORAMA Study. Diabetes Metab 41 (2015), 470–479.